FIKE v. GLOBAL PHARMA HEALTHCARE PRIVATE, LTD

CourtDistrict Court, E.D. Pennsylvania
DecidedJuly 18, 2024
Docket5:23-cv-02981
StatusUnknown

This text of FIKE v. GLOBAL PHARMA HEALTHCARE PRIVATE, LTD (FIKE v. GLOBAL PHARMA HEALTHCARE PRIVATE, LTD) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
FIKE v. GLOBAL PHARMA HEALTHCARE PRIVATE, LTD, (E.D. Pa. 2024).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA _____________________________________

DONNA FIKE, : Plaintiff, : : v. : No. 5:23-cv-2981 : GLOBAL PHARMA HEALTHCARE : PRIVATE, LTD; EZRICARE, LLC; : AMAZON.COM, INC.; and EZRIRX, LLC; : Defendant. : _____________________________________

O P I N I O N Defendant Amazon’s Motion to Dismiss, ECF No. 22 – Granted in part, Denied in part

Joseph F. Leeson, Jr. July 18, 2024 United States District Judge

I. INTRODUCTION This case is about eye drops that were contaminated with a virulent type of bacteria. The eye drops were manufactured and marketed by Defendant Global Pharma Healthcare Private, Ltd., EzriCare, LLC, and EzriRx LLC. Defendant Amazon.com, Inc. sold them to Plaintiff Donna Fike. Her eye became infected from the drops, and eventually had to be removed. She sued Global Pharma Healthcare Private, EzriCare, EzriRx, and Amazon for strict products liability, failure to warn, negligence, negligent/reckless misrepresentation, breach of express warranty, breach of implied warranty of merchantability, violation of the Pennsylvania Unfair Trade Practices and Consumer Protection Law (“UTPCPL”), negligent infliction of emotional distress, and punitive damages. Amazon has moved to dismiss the counts for strict liability, negligence, negligent/reckless misrepresentation, breach of express warranty, violation of the UTPCPL, and punitive damages. For the reasons set forth below, the motion is granted in part and denied in part. 1 II. BACKGROUND The Amended Complaint avers the following facts: Fike purchased artificial tears made and marketed by Global Pharma Healthcare Private, EzriCare, and EzriRx on May 16, July 23, and December 10 of 2022. See Am. Compl. ¶ 32, ECF No. 19. Each time she bought the product from Amazon. Id. The Center for Disease Control (“CDC”) began investigating EzriCare’s artificial tears in May 2022 after reports of eye infections caused by the Pseudomonas Aeruginosa bacteria. Id. at

¶ 22. In late January of 2023, the CDC informed EzriCare that it was investigating its eye drops. Id. at ¶ 27. On February 1, 2023, Global Pharma Healthcare Private voluntarily recalled the EzriCare artificial tears, and the next day the FDA issued a statement warning consumers not to purchase EzriCare artificial tears. Id. at ¶¶ 29, 30. During this time, Donna Fike was using the artificial tears. By the end of January, 2023, her left eye was infected with the Pseudomonas Aeruginosa bacteria. Id. at ¶ 40. On February 5, 2023, it was determined that antibiotics would not help the infection, and Fike’s left eye was surgically removed. Id. at ¶ 46. Fike filed her first complaint on August 3, 2023, against Global Pharma Healthcare Private, EzriCare, EzriRx, and Amazon. See ECF No. 1. On September 14, 2023, Amazon filed

a motion to dismiss. See ECF No. 12. Fike filed an amended complaint on September 28, 2023. See Am. Compl., ECF No. 19. The Amended Complaint sets forth the following counts, each against all Defendants: Count I- Strict Products Liability Count II- Strict Products Liability-Failure to Warn Count III- Negligence Count IV- Negligent/Reckless Misrepresentation Count V- Breach of Express Warranty Count VI- Breach of Implied Warranty of Merchantability Count VII- UTPCPL 2 Count VIII- Negligent Infliction of Emotional Distress Count IX- Punitive Damages

Amazon filed a Motion to Dismiss the Amended Complaint on October 12, 2023. See Mot., ECF No. 22. Amazon argues: (1) the Amended Complaint should be dismissed as to Amazon because it lacks specificity and is an impermissible “shotgun pleading” in violation of Rule 8(a)(2) and Third Circuit precedent; (2) Counts I and III should be dismissed as to Amazon to the extent those claims are premised on a post-sale duty to recall because Pennsylvania law does not recognize such a duty; (3) Count IV should be dismissed as to Amazon because it is not supported by any duty and because Fike does not adequately plead that claim under Pennsylvania law and the heightened standard required under Rule 9(b); (4) Count V should be dismissed as to Amazon because Fike fails to adequately plead that claim under Pennsylvania law; (5) Count VII should be dismissed as to Amazon because the UTPCPL does not permit claims relating to personal injury; and (6) Count IX should be dismissed as to Amazon because Pennsylvania law does not recognize punitive damages as an independent cause of action and Fike does not otherwise plead facts sufficient to warrant the imposition of punitive damages.1 See id. Fike responded on October 26, 2023, and Amazon replied November 2, 2023.2 See ECF Nos. 27, 29.

1 The second, fifth, and sixth arguments were also presented in Amazon’s motion to dismiss the first complaint. See ECF No. 12. 2 Defendants EzriCare and EzriRx have also filed motions to dismiss. See ECF Nos. 23- 24. See also ECF Nos. 31-32. Fike filed briefs in opposition to the motions. See ECF Nos. 25- 26. Thereafter, Fike filed a motion pursuant to Federal Rule of Civil Procedure 41(a)(2) to voluntarily dismiss EzriCare and EzriRx. See ECF Nos. 34. Amazon opposes voluntary dismissal stating, inter alia, that Fike provides no basis for her belief that these Defendants are insolvent and that it intends to file crossclaims against EzriCare and EzriRx if its Motion to Dismiss is denied. See ECF No. 35. Because an answer to the Amended Complaint has not been filed, Fike does not need permission of the Court to voluntarily dismiss its claims against EzriCare and EzriRx. See Fed. R. Civ. P. 41(a)(1)(A)(i) (“[T]he plaintiff may dismiss an action without a court order by filing: (i) a notice of dismissal before the opposing party serves either an answer or a motion for summary judgment.”). Accordingly, this Court is not inclined to deny Fike’s request, especially at this early stage of the proceedings. However, to eliminate any unnecessary expense and added delay by requiring Amazon to serve any crossclaim on EzriCare 3 III. LEGAL STANDARDS A. Motion to Dismiss, Rule 12(b)(6) - Review of Applicable Law In rendering a decision on a motion to dismiss, this Court must “accept all factual allegations as true [and] construe the complaint in the light most favorable to the plaintiff.” Phillips v. Cnty. of Allegheny, 515 F.3d 224, 233 (3d Cir. 2008) (quoting Pinker v. Roche Holdings Ltd., 292 F.3d 361, 374 n.7 (3d Cir. 2002)) (internal quotation marks omitted). Only if “the ‘[f]actual allegations . . . raise a right to relief above the speculative level’” has the plaintiff

stated a plausible claim. Id. at 234 (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 540, 555 (2007)). “A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). However, “the tenet that a court must accept as true all of the allegations contained in a complaint is inapplicable to legal conclusions.” Id. (explaining that determining “whether a complaint states a plausible claim for relief . . . [is] a context-specific task that requires the reviewing court to draw on its judicial experience and common sense”).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Tellabs, Inc. v. Makor Issues & Rights, Ltd.
551 U.S. 308 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Phillips v. County of Allegheny
515 F.3d 224 (Third Circuit, 2008)
Hunt v. United States Tobacco Co.
538 F.3d 217 (Third Circuit, 2008)
Jefferies v. Ameriquest Mortgage Co.
543 F. Supp. 2d 368 (E.D. Pennsylvania, 2008)
Bilt-Rite Contractors, Inc. v. Architectural Studio
866 A.2d 270 (Supreme Court of Pennsylvania, 2005)
Ash v. Continental Insurance
932 A.2d 877 (Supreme Court of Pennsylvania, 2007)
Bortz v. Noon
729 A.2d 555 (Supreme Court of Pennsylvania, 1999)
Weinberg v. Sun Co., Inc.
777 A.2d 442 (Supreme Court of Pennsylvania, 2001)
Tennis v. Ford Motor Co.
730 F. Supp. 2d 437 (W.D. Pennsylvania, 2010)
Erie Insurance Company v. Amazon.com, Inc.
925 F.3d 135 (Fourth Circuit, 2019)
Goodman v. PPG Industries, Inc.
849 A.2d 1239 (Superior Court of Pennsylvania, 2004)
Lorenz v. CSX Corp.
1 F.3d 1406 (Third Circuit, 1993)
Runner v. Bard
108 F. Supp. 3d 261 (E.D. Pennsylvania, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
FIKE v. GLOBAL PHARMA HEALTHCARE PRIVATE, LTD, Counsel Stack Legal Research, https://law.counselstack.com/opinion/fike-v-global-pharma-healthcare-private-ltd-paed-2024.